Forte Biosciences (FBRX) Notes Payables (2016 - 2020)

Forte Biosciences (FBRX) has 5 years of Notes Payables data on file, last reported at $5.0 million in Q1 2020.

• Notes Payables for Q1 2020 came in at $5.0 million, up 126.0% year-over-year; the trailing twelve-month figure through Mar 2020 was $5.0 million (up 126.0% YoY), and the FY2019 annual result was $4.7 million, changed N/A from the prior year.
• Notes Payables advanced to $5.0 million in Q1 2020 per FBRX's latest filing, from $4.7 million in the prior quarter.
• Over five years, Notes Payables peaked at $27.8 million in Q3 2019 and troughed at $2.2 million in Q1 2019.
• A 5-year average of $7.9 million and a median of $7.2 million in 2016 frame the typical range for Notes Payables.
• The sharpest annual moves came in 2019 and 2020: Notes Payables slumped 69.39% in 2019, then soared 126.0% in 2020.
• A 5-year view of Notes Payables shows it stood at $7.2 million in 2016, then changed by 0.0% to $7.2 million in 2017, then changed by 0.0% to $7.2 million in 2018, then sank by 34.11% to $4.7 million in 2019, then advanced by 5.0% to $5.0 million in 2020.
• Business Quant data shows FBRX's Notes Payables at $5.0 million in Q1 2020, $4.7 million in Q4 2019, and $27.8 million in Q3 2019.